PURPOSE: Estrogen receptor beta (ERbeta) is the second identified receptor mediating the effects of estrogen on target tissues. The role of ERbeta in cancer pathobiology is largely unknown, because specific antibodies have not been available until recently. Initial studies have shown that ERbeta expression declines in breast, ovarian, prostatic, and colon carcinomas. Tamoxifen, a synthetic anti-estrogen compound that is a mixed agonist/antagonist of estrogen receptor alpha (ERalpha) and a pure antagonist of ERbeta, has moderate beneficial effects in human astrocytic neoplasms. However, most published studies agree that glial tumors do not express ERalpha. The purpose of this study was to explore the expression of ERbeta in astrocytic neoplasms. METHODS: ERbeta expression was monitored immunohistochemically in 56 cases of astrocytomas of all grades (grade I-IV) and in adjacent non-neoplastic brain tissue. RESULTS: Moderate or strong nuclear immunopositivity was obtained in non-neoplastic astrocytes and in low-grade astrocytomas, whereas the majority of high-grade tumors were immunonegative or displayed weak immunoreactivity. The progressive decline in ERbeta expression paralleled the increase in tumor grade. CONCLUSIONS: In as much as ERbeta is possibly the only ER expressed in astrocytes, its decreased expression may play an important role in astrocytic tumor initiation and in the potential response of glial neoplasms to tamoxifen.
PURPOSE:Estrogen receptor beta (ERbeta) is the second identified receptor mediating the effects of estrogen on target tissues. The role of ERbeta in cancer pathobiology is largely unknown, because specific antibodies have not been available until recently. Initial studies have shown that ERbeta expression declines in breast, ovarian, prostatic, and colon carcinomas. Tamoxifen, a synthetic anti-estrogen compound that is a mixed agonist/antagonist of estrogen receptor alpha (ERalpha) and a pure antagonist of ERbeta, has moderate beneficial effects in humanastrocytic neoplasms. However, most published studies agree that glial tumors do not express ERalpha. The purpose of this study was to explore the expression of ERbeta in astrocytic neoplasms. METHODS:ERbeta expression was monitored immunohistochemically in 56 cases of astrocytomas of all grades (grade I-IV) and in adjacent non-neoplastic brain tissue. RESULTS: Moderate or strong nuclear immunopositivity was obtained in non-neoplastic astrocytes and in low-grade astrocytomas, whereas the majority of high-grade tumors were immunonegative or displayed weak immunoreactivity. The progressive decline in ERbeta expression paralleled the increase in tumor grade. CONCLUSIONS: In as much as ERbeta is possibly the only ER expressed in astrocytes, its decreased expression may play an important role in astrocytic tumor initiation and in the potential response of glial neoplasms to tamoxifen.
Authors: P Pujol; J M Rey; P Nirde; P Roger; M Gastaldi; F Laffargue; H Rochefort; T Maudelonde Journal: Cancer Res Date: 1998-12-01 Impact factor: 12.701
Authors: P A Konstantinopoulos; A Kominea; G Vandoros; G P Sykiotis; P Andricopoulos; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou Journal: Eur J Cancer Date: 2003-06 Impact factor: 9.162
Authors: Gangadhara R Sareddy; Binoj C Nair; Vijay K Gonugunta; Quan-guang Zhang; Andrew Brenner; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi Journal: Mol Cancer Ther Date: 2012-03-21 Impact factor: 6.261
Authors: Jinyou Liu; Gangadhara R Sareddy; Mei Zhou; Suryavathi Viswanadhapalli; Xiaonan Li; Zhao Lai; Rajeshwar R Tekmal; Andrew Brenner; Ratna K Vadlamudi Journal: Cancer Res Date: 2018-04-16 Impact factor: 12.701
Authors: J M Dueñas Jiménez; A Candanedo Arellano; A Santerre; S Orozco Suárez; H Sandoval Sánchez; I Feria Romero; R López-Elizalde; M Alonso Venegas; B Netel; B de la Torre Valdovinos; S H Dueñas Jiménez Journal: J Neurooncol Date: 2014-07-09 Impact factor: 4.130